Orthopedic showcase: From gene therapy to treatments for new kinds of battlefield injuries March 1, 2007 By Trista Morrison
BiPar Raises $35M Series B For PARP Inhibitor Program Feb. 27, 2007 By Trista Morrison With a $35 million Series B financing in hand, BiPar Sciences Inc. expects to generate Phase II data with lead product candidate BSI-201, advance a second compound into the clinic and get a third product through IND filing. (BioWorld Today)Read More
